Bibliographie : "Substances psychédéliques et prise en charge des PTSD", Dr Christian Sueur, GRECC, mars 2023
Lire la suiteBibliographie MDMA - Ecstasy Docteur Christian Sueur, GRECC, mars 2023 MDMA : généralités, sociologie…, pp 1 - 3. MDMA : pharmacologie, pp 4 - 9. MDMA : neurophysiologie, pp 10 - 15. MDMA : toxicologie, pp 16 - 22. MDMA : analyses pharmacologiques, « réduction des risques », pp 23 - 24. MDMA : psychopathologie, pp 25 - 26. MDMA : enthéogénie, p 27. MDMA : thérapeutique, pp 28 - 34.
Lire la suiteEditorial: Psychological Aspects of Cannabis Use and Cannabis Use Disorder Daniel Feingold, Eva Hoch, Aviv Weinstein and Wayne Hall Frontiers in Psychiatry, 2021, Volume 12 | Article 789197 doi : 10.3389/fpsyt.2021.789197 Editorial on the Research Topic : Psychological Aspects of Cannabis Use and Cannabis Use Disorder Keywords : cannabis, marijuana, cannabis use disorder, psychology, cognition, emotion An increasing global prevalence of cannabis use has produced increased treatment seeking for Cannabis Use Disorder (CUD) and an increased research effort to identify factors associated with initiation of cannabis use, transitions to regular cannabis use and the onset of CUD (1, 2). The majority of empirical studies focus on biological and [...]
Lire la suiteCBD FOR PAIN : WHAT DOES THE SCIENCE SAY ? A new book by three distinguished scientists reviews the current status of CBD as a treatment for acute and chronic illness. By Linda A. Parker, Erin M. Rock, and Raphael Mechoulam on October 04, 2022 Excerpted from CBD: What Does the Science Say ? by Linda A. Parker, Erin M. Rock, and Raphael Mechoulam, published by MIT Press (2022, 309 pp.). A large proportion of medicinal cannabis patients are using cannabis to treat pain syndromes, particularly for chronic pain alleviation. Cannabis use for unmanageable pain has been shown to reduce the dose of opiates [...]
Lire la suiteAOC : jeudi 16 mars 2023 Expériences de légalisation du cannabis, un premier bilan Par Ivana Obradovic POLITISTE Le Conseil économique, social et environnemental vient de publier un avis prônant la légalisation du cannabis en France. La récurrence du débat public sur le statut légal du cannabis invite à dresser un bilan des politiques menées pour « réguler » ce marché. Après dix ans de mise en œuvre dans quelques États outre-Atlantique, que sait-on des expériences de légalisation mises en place ? Le bilan de ces réformes apparaît contrasté, au regard de leurs effets économiques et des conséquences sanitaires. « Cannabis : sortir du statu [...]
Lire la suiteThe Rapid Rise in Investment in Psychedelics— Cart Before the Horse Joshua PHELPS, Ravi N. SHAH, Jeffrey A. LIEBERMAN, JAMA Psychiatry, 2022, 79, (3), 189-190. Doi : 10.1001/jamapsychiatry.2021.3972 Anticipating a renaissance, many psychedelic medicine companies have conducted initial public offerings, where in private companies first issue news hares of stock for sale to the public, making the companies publicly traded entities.1 As of this writing, there are more than 50 publicly traded companies related to the development or administration of psychedelic like drugs in the US, with at least 3 valued at more than $1 billion. The market for psychedelic substances is projected to [...]
Lire la suiteLegalizing MDMA-Assisted Psychotherapy for the Treatment of Trauma-Related Mental Health Disorders Prakash THAMBIPILLAI Revue YOUR, 2021, Review 8, 51-61 3, 4–methylenedioxymethamphetamine, or MDMA as it is commonly known, is classified as a “Schedule 1” substance in Canada and the United States. For decades, the compound has been shrouded by the stigma of being a dangerous party drug thought to kill brain cells and be severely addictive. However, when it was originally discovered, it was experimentally used in clinical settings as an adjunct to therapy. This idea is now resurfacing as researchers are turning back to MDMA as an innovative way to treat trauma-related [...]
Lire la suiteThe Effects of Cannabinoids on Sleep Bhanu Prakash Kolla, Lisa Hayes, Chaun Cox, Lindy Eatwell, Mark Deyo-Svendsen , and Meghna P. Mansukhani Journal of Primary Care & Community Health, 2022, Volume 13, 1–9. Doi : 10.1177/21501319221081277 Abstract The use of cannabis products to help with sleep and various other medical conditions by the public has increased significantly in recent years. Withdrawal from cannabinoids can lead to sleep disturbance. Here, we describe a patient who developed significant insomnia leading to worsening anxiety, mood, and suicidal ideation in the setting of medical cannabis withdrawal, prompting presentation to the Emergency Department and inpatient admission. There is a limited [...]
Lire la suiteCannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists Gniewko Wieckiewicz, Iga Stokłosa, Maciej Stokłosa, Piotr Gorczyca and Robert Pudlo Frontiers in Psychiatry, March 2022 | Volume 13 | Article 837946 doi : 10.3389/fpsyt.2022.837946 Cannabis sativa, whose flowers are also known as marijuana or marihuana, is a recreational plant that contains many chemicals that are constantly being studied by scientists around the world. One of these substances is cannabidiol (CBD), which has gained widespread popularity on the internet as a cure for mental health problems, leading many people to use CBD to self-treat depression and anxiety. This [...]
Lire la suiteBIBLIOGRAPHIE : Cannabinoïdes et maladies neurodégénératives Dr Christian Sueur, GRECC, mars 2022.
Lire la suite